With a total of 39.1 million doses delivered to the Philippines, AstraZeneca’s COVID-19 vaccine is estimated to have prevented 52,224 deaths locally, an independent assessment of vaccine effectiveness shows.
Lotis Ramin, Country President, AstraZeneca (Philippines) Ltd., said: “Primary and booster vaccination coverage remains critically important, and this new data further demonstrates that our vaccine is highly effective in protecting against COVID-19’s worst outcome. AstraZeneca remains fully committed to continuing our work with the Philippine government, local government units, and the private sector to ensure each and every Filipino is vaccinated and boosted as a priority.”
The analysis conducted by Airfinity, a health data firm, covers the period from 8 December 2020 to 8 December 2021. The data showed that globally, the AstraZeneca vaccine is estimated to have saved more than 6.3 million lives.
In addition to the human health impact, COVID-19 vaccinations also created significant and measurable economic benefits, according to recent research from the consultancy KPMG, which was commissioned by AstraZeneca. In the Philippines, mass vaccinations from January to October 2021 – covering the first stages of the country’s vaccine roll-out – are estimated to have saved US$3.2 billion in pandemic healthcare costs.
Since the COVID-19 pandemic began, AstraZeneca and its global partners have released more than three billion vaccine doses to more than 180 countries, and approximately two-thirds of these doses have been delivered to low- and lower-middle income countries.
AstraZeneca’s vaccine, which is a viral vector vaccine, and mRNA COVID-19 vaccines, both provide high protection against hospitalization (91.3-92.5%) and death (91.4-93.3%) after two doses regardless of age, with no statistical difference between them.
